TITLE

Predictors and survival in patients with melanoma brain metastases

AUTHOR(S)
Bottoni, Ugo; Clerico, Rita; Paolino, Giovanni; Ambrifi, Marina; Corsetti, Paola; Calvieri, Stefano
PUB. DATE
March 2013
SOURCE
Medical Oncology;Mar2013, Vol. 30 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Brain metastases (BM) are one of the most frequent neurological complications of cancers. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10-40 %, and many patients have subclinical BM (>73 %). We computer-searched the clinical records of all our patients registered into a database to identify patients that presented or developed BM. A total of 49 patients with melanoma BM were included in our analysis. General time to brain metastases (TTBM) was 23 months. The nonparametric test between TTBM and the single variables showed an association between TTBM and Breslow thickness ( p < 0.0076; Spearman's coefficient-0.411), ulceration ( p = 0.0656; Spearman's coefficient-0.287) and positive sentinel lymph node ( p < 0.0015; Spearman's coefficient-0.475). Performing multiple regression, positive SLN remained the only, statistically significant, predictive variable ( p < 0.01). Regarding the first melanoma site, the axial sites were more likely to develop BM than peripheral ones ( p < 0.001). The analysis of brain metastasis survival (BMS) with Kaplan-Meier curves has resulted in a median survival rate of 6 months (range 1-134 months) and was strongly related to response to treatment, number of parenchymal lesions, presence or absence of symptoms. The results of the current analysis revealed clinical and primary tumor characteristics associated with the development of BM, TTBM, and BMS. The SNL was found to be the strongest predictor for BM development.
ACCESSION #
85859775

 

Related Articles

  • Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology. Gumusay, Ozge; Coskun, Ugur; Akman, Tülay; Ekinci, Ahmet; Kocar, Muharrem; Erceleb, Özlem; Yazıcı, Ozan; Kaplan, Mehmet; Berk, Veli; Cetin, Bulent; Taskoylu, Burcu; Yildiz, Ayhan; Goksel, Gamze; Alacacioglu, Ahmet; Demirci, Umut; Algin, Efnan; Uysal, Mukremin; Oztop, Ilhan; Oksuzoglu, Berna; Dane, Faysal // Journal of Cancer Research & Clinical Oncology;Jan2014, Vol. 140 Issue 1, p151 

    Background: The development of brain metastases (BMs) was associated with poor prognosis in melanoma patients. Patients with BMs have a median survival of <6 months. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10-40 %. Our aim was to identify...

  • Epidemiology and prognosis of brain metastases. Stelzer, Keith J. // Surgical Neurology International;2013, Vol. 4 Issue 5, pS192 

    A substantial, but uncertain, number of patients with cancer develop brain metastases. Risk of brain metastasis is recognized to vary with type of primary cancer. Within specific types of primary cancer, prognostic factors for development of brain metastases are being recognized. Recent data...

  • Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Pogoda, Katarzyna; Niwińska, Anna; Murawska, Magdalena; Pieńkowski, Tadeusz // Medical Oncology;Mar2013, Vol. 30 Issue 1, p1 

    The aim of the study was to assess the rate, pattern, and time of recurrence in patients with triple-negative breast cancer (TNBC) and to evaluate factors influencing recurrence and overall survival in this group of patients. Out of 2,534 consecutive breast cancer patients diagnosed between...

  • Seed, soil, and beyond: The basic biology of brain metastasis. Ramakrishna, Rohan; Rostomily, Robert // Surgical Neurology International;2013, Vol. 4 Issue 5, pS256 

    First invoked by Paget, the seed and soil hypothesis suggests that the successful growth of metastatic cells depends on the interactions and properties of cancer cells (seeds) and their potential target organs (soil). In the context of the seed and soil hypothesis this review examines recent...

  • Gliadel for brain metastasis. Abel, Taylor J.; Ryken, Timothy; Lesniak, Maciej S.; Gabikian, Patrik // Surgical Neurology International;2013, Vol. 4 Issue 5, pS289 

    With therapies for systemic malignancy improving, life expectancy for cancer patients is becoming increasingly dependent on control of brain metastatic disease. Despite improvements in surgical and radiotherapy modalities for control of brain metastasis, the prognosis for patients with brain...

  • Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Berghoff, Anna S; Fuchs, Elisabeth; Spanberger, Thomas; Zielinski, Christoph; Bartsch, Rupert; Preusser, Matthias; Prayer, Daniela; Heinzl, Harald; Birner, Peter; Ricken, Gerda; Widhalm, Georg; Dieckmann, Karin; Mlecnik, Bernhard; Bindea, Gabriela; Bilocq, Amelie; Galon, Jerome; Hackl, Monika // OncoImmunology;Jan2016, Vol. 5 Issue 1, p1 

    The immune microenvironment of the brain differs from that of other organs and the role of tumor-infiltrating lymphocytes (TILs) in brain metastases (BM), one of the most common and devastating complication of cancer, is unclear. We investigated TIL subsets and their prognostic impact in...

  • Brain metastases: pathobiology and emerging targeted therapies. Preusser, Matthias; Capper, David; Ilhan-Mutlu, Aysegül; Berghoff, Anna; Birner, Peter; Bartsch, Rupert; Marosi, Christine; Zielinski, Christoph; Mehta, Minesh; Winkler, Frank; Wick, Wolfgang; Deimling, Andreas // Acta Neuropathologica;Feb2012, Vol. 123 Issue 2, p205 

    Brain metastases (BM) are common in cancer patients and are associated with high morbidity and poor prognosis, even after intensive multimodal therapy including resection, radiotherapy (stereotactic radiosurgery or whole brain radiotherapy) and chemotherapy. However, advances in the...

  • Whole brain helical Tomotherapy with integrated boost for brain metastases in patients with malignant melanoma--a randomized trial. Hauswald, Henrik; Habl, Gregor; Krug, David; Kehle, Denise; Combs, Stephanie E.; Bermejo, Justo Lorenzo; Debus, Jürgen; Sterzing, Florian // Radiation Oncology;2013, Vol. 8 Issue 1, p1 

    Background Patients with malignant melanoma may develop brain metastases during the course of the disease, requiring radiotherapeutic treatment. In patients with 1-3 brain metastases, radiosurgery has been established as a treatment option besides surgery. For patients with 4 or more brain...

  • Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer. Xiao-hui Ge; Qiang Lin; Xiao-cang Ren; Yue-e Liu; Xue-ji Chen; Dong-ying Wang; Yong-qiang Wang; Bin Cao; Zhi-gang Li; Miao-ling Liu // Radiation Oncology;2013, Vol. 8 Issue 1, p1 

    Background Patients with brain metastases from lung cancer have poor prognoses and short survival time, and they are often excluded from clinical trials. Whole-cranial irradiation is considered to be the standard treatment, but its efficacy is not satisfactory. The purpose of this phase II...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics